Loss of AMPKα1 Expression Is Associated with Poor Survival in Melanoma Patients  by Bhandaru, Madhuri et al.
surgery in the Department of Otolaryn-
gology at Long Island Jewish (LIJ) Med-
ical Center after written, informed
consent. Use of these tissues was
approved by the Institutional Review
Board of the Feinstein Institute for Med-
ical Research.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by grants 5R01DC008579
and 1F32DC011446 from the National Institute
on Deafness and Other Communication
Disorders. The content is solely the responsibility
of the authors and does not necessarily represent
the official views of the National Institute on
Deafness and Other Communication Disorders or
the National Institutes of Health.
Alexandra V. Lucs1,
Allan L. Abramson1,2 and
Bettie M. Steinberg1,2,3
1Feinstein Institute for Medical Research, North
Shore-LIJ Health System, Manhasset, New York,
USA; 2Department of Otolaryngology and
Communicative Disorders, Hofstra North
Shore-LIJ School of Medicine, New Hyde Park,
New York, USA and 3Department of Molecular
Medicine, Hofstra North Shore-LIJ School of
Medicine, Manhasset, New York, USA
E-mail: alucs@nshs.edu
REFERENCES
Bonilla-Delgado J, Bulut G, Liu X et al. (2012)
The E6 oncoprotein from HPV16 enhances
the canonical Wnt/b-catenin pathway in skin
epidermis in vivo. Mol Cancer Res 10:250–8
Brembeck FH, Rosa´rio M, Birchmeier W (2006)
Balancing cell adhesion and Wnt signaling,
the key role of beta-catenin. Curr Opin Genet
Dev 16:51–9
DeVoti JA, Rosenthal DW, Wu R et al. (2008) Immune
dysregulation and tumor-associated gene changes
in recurrent respiratory papillomatosis: a paired
microarray analysis. Mol Med 14:608–17
Doorbar J, Quint W, Banks L et al. (2012) The
biology and life-cycle of human papilloma-
viruses. Vaccine 30(Suppl 5):F55–70
Hartsock A, Nelson WJ (2008) Adherens and tight
junctions: structure, function and connections
to the actin cytoskeleton. Biochim Biophys
Acta 1778:660–9
Heuberger J, Birchmeier W (2010) Interplay of
cadherin-mediated cell adhesion and canoni-
cal Wnt signaling. Cold Spring Harb Perspect
Biol 2:a002915
Johnston D, Hall H, DiLorenzo TP et al. (1999)
Elevation of the epidermal growth factor
receptor and dependent signaling in human
papillomavirus-infected laryngeal papillomas.
Cancer Res 59:968–74
Lock FE, Hotchin NA (2009) Distinct roles for
ROCK1 and ROCK2 in the regulation of
keratinocyte differentiation. PLoS ONE 4:e8190
Longworth MS, Laimins LA (2004) Pathogenesis of
human papillomaviruses in differentiating
epithelia. Microbiol Mol Biol Rev 68:362–72
McMullan R, Lax S, Robertson VH et al. (2003)
Keratinocyte differentiation is regulated by the
Rho and ROCK signaling pathway. Curr Biol
13:2185–9
Meng W, Takeichi M (2009) Adherens junction:
molecular architecture and regulation. Cold
Spring Harb Perspect Biol 1:a002899
Nusse R (2009) Wnt Target genes http://www.
stanford.edu/group/nusselab/cgi-bin/wnt/target_
genes (accessed 2012)
Pedersen E, Wang Z, Stanley A et al. (2012) RAC1
in keratinocytes regulates crosstalk to immune
cells by Arp2/3-dependent control of STAT1.
J Cell Sci 125:5379–90
Pore N, Jiang Z, Gupta A et al. (2006) EGFR
tyrosine kinase inhibitors decrease VEGF
expression by both hypoxia-inducible factor
(HIF)-1-independent and HIF-1-dependent
mechanisms. Cancer Res 66:3197–204
Steinberg BM, Meade R, Kalinowski S et al. (1990)
Abnormal differentiation of human papillo-
mavirus-induced laryngeal papillomas. Arch
Otolaryngol Head Neck Surg 116:1167–71
Loss of AMPKa1 Expression Is Associated with Poor Survival
in Melanoma Patients
Journal of Investigative Dermatology (2014) 134, 1763–1766; doi:10.1038/jid.2014.26; published online 13 February 2014
TO THE EDITOR
Metastatic melanoma is notorious for
its rapid progression, resistance to con-
ventional chemotherapy, and poor prog-
nosis, as only 14% of patients with
metastatic melanoma survive for 5 years
(Miller and Mihm, 2006). There has been
limited success in the chemotherapy
of melanoma, with only a hand-
ful of Food and Drug Administration-
approved drugs (Finn et al., 2012).
Although BRAFV600E-specific inhibitor,
vemurafinib showed promise in treat-
ment of melanoma, its effectiveness
has been limited to patients harboring
the V600E mutation in BRAF gene;
moreover, recent information suggest
the development of lethal resistance to
vemurafinib (Finn et al., 2012). It was
shown earlier that BRAF inhibits the
activation of AMP-activated protein
kinase (AMPK; Zheng et al., 2009).
AMPK is a key regulator of cell metabo-
lism and its activation has been reported
to have antineoplastic effects (Kim and
He, 2013). However, the role of AMPK
in cancer has been controversial with
studies showing the ‘prosurvival’ effects
of AMPK (Liang and Mills, 2013), and
only a few studies reported on the
relationship between AMPK expression
and cancer progression. To our knowl-
edge, AMPK expression has never been
analyzed in melanoma patients. AMPK
consists of catalytic a-subunit and regu-
latory b- and g-subunits, and in mam-
mals, each subunit occurs as multiple
isoforms (Kim and He, 2013). AMPKa1
is reportedly associated with tumor sup-
pressor functions of AMPK (Lee et al.,
2010; Liang and Mills, 2013; Zheng
et al., 2013) and the present study
was therefore undertaken to analyze
the correlation between AMPKa1
expression and patient survival using
the tissue samples collected from mela-
noma patients.
We performed tissue microarray
analysis of AMPKa1 expression in 128Accepted article preview online 17 January 2014; published online 13 February 2014
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melanoma patients (Supplementary
Table S1 online), and the staining
pattern is illustrated in Supplementary
Figure S1 online. On the basis of the
area under the receiver operating char-
acteristic curve values, the best cutoff
immunoreactive score (IRS) was deter-
mined as IRS-4 (Supplementary Figure
S2 online; Remmele and Stegner, 1987).
The Kruskal–Wallis and w2-test analysis
of expression using IRS-4 as the cutoff
showed that the expression of AMPKa1
was significantly increased from dys-
plastic nevi to primary melanoma, and
then decreased significantly from primary
to metastatic melanoma (Figure 1).
Furthermore, high staining of AMPKa1
tended to correlate with presence of
ulcerated tumors, whereas low AMPKa1
staining was more frequently seen in
tumors at sun-exposed sites (Supplemen-
tary Table S2 online). The increase in
expression of AMPKa1 in primary mela-
noma patients is in agreement with the
previous study on chromosomal alte-
rations in desmoplastic melanoma,
which reported amplification in AMPK
gene (Pryor et al., 2011). Interestingly,
evidence from literature presents a dual
role of AMPK in melanoma. On one
hand, activation of AMPK by metformin
has been shown to inhibit melanoma
invasion and metastasis both in vitro
and in vivo (Cerezo et al., 2013), on
the other hand, AMPK was shown to
regulate the expression of micropthalmia-
induced transcription factor, and reported
to positively influence the growth of
BRAFV600E-driven melanoma by upregula-
ting vascular endothelial growth factor
(Martin et al., 2012; Borgdorff et al.,
2013).
The Kaplan–Meier analysis of survival
in the patients (primary and metastatic
melanoma combined) revealed that the
patients with low AMPKa1 expression
had significantly worse overall and
disease-specific 5-year survival (Supple-
mentary Figures S3A and B online), but
when only primary melanoma patients
were analyzed the association between
AMPKa1 expression and patient survival
was not statistically significant (Supple-
mentary Figures S3C and D online).
Intriguingly, multivariate but not uni-
variate Cox proportional hazards regres-
sion analysis showed that AMPKa1 was
an independent prognostic marker when
age, gender, tumor subtype, thickness,
and ulceration were used as variables
(Table 1 and Supplementary Table S3
online). We think that the reason could
be due to interaction of AMPKa1 with
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Figure 1. AMPKa1 expression in melanoma. (a–f) Representative images of AMPKa1 immunohistochemical staining in human melanocytic lesions
(bar ¼ 100mm in upper panels and 25mm in lower panels). (a, d) Dysplastic nevi with low (IRS, 0–4) and (b, e) primary melanoma and (c, f) metastatic melanoma
with high (IRS, 6–12) AMPKa1 staining. (g) AMPKa1 staining is significantly increased from dysplastic nevi (DN) to primary melanoma (PM) and decreased from
primary melanoma to metastatic melanoma (MM) by the Kruskal–Wallis test. *Po0.05, **Po0.005. (h) Percentage of strong AMPKa1 staining is significantly
increased from dysplastic nevi to primary melanoma and decreased from primary melanoma to metastatic melanoma by w2-test. *Po0.05, **Po0.005.
White filled bars represent low, and black filled bars represent high AMPKa1 staining.
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the variables such as subtype and
ulceration, and possibly also because
of variability of the correlation between
AMPKa1 expression and patient sur-
vival when analyzed alone, and when
analyzed together with other variables.
Further studies are therefore warranted
to clarify the association between
AMPKa1 expression and patient survi-
val. Although we could not find any
reports on AMPKa1 expression and
patient survival, previous studies in
hepatocellular carcinoma and lung
cancer patients showed that low expres-
sion of activated AMPK (phospho-
AMPK) correlated with poor prognosis,
which support our present findings
(William et al., 2012; Zheng et al.,
2013). Recently, AMPK was reported
to phosphorylate BRAF at Ser729 posi-
tion, leading to association of BRAF
with 14-3-3 proteins and to attenuation
of the MEK-ERK signaling (Shen et al.,
2013). Our group has previously
reported the association between BRAF
expression and melanoma progression
and patient survival, and the present
study had 116 cases that were also
used for the analysis of BRAF expres-
sion (see Supplementary Information
online for reference). Analysis of corre-
lation between BRAF and AMPKa1
expression using the common cases
revealed that there was a tendency for
inverse correlation between the two
markers, but the association was not
statistically significant (Supplementary
Figure S3 online). The Kaplan–Meier
analysis of the survival data from these
common cases showed that irrespective
of BRAF expression, patients with high
AMPKa1 expression had comparatively
better overall and disease-specific 5-
year survival indicating the importance
of AMPK in patient prognosis
(Supplementary Figure S4 online).
The cross talk between mitogen-
activated protein kinase pathway and
energy sensing pathways is gaining
importance, and our findings shed
further light on the relationship between
BRAF and AMPK. Our results support
the recent findings on therapeutic bene-
fits of phenformin in melanoma (Yuan
et al., 2013) and encourage for further
research on the possible effects of com-
bining BRAF inhibitors and AMPK activa-
tors in melanoma treatment. Owing to
limitations in sample availability, we
could not use a larger database to ana-
lyze the AMPKa1 expression, and we think
that the correlation between AMPKa1
expression and patient survival needs to
be reproduced in a larger cohort. More
studies with more patient information
would conclusively determine the useful-
ness of AMPKa1 expression in mela-
noma prognosis and treatment. Never-
theless, our study identifies the role of
AMPKa1 in melanoma prognosis and
underscores the importance for further
research.
The use of human skin tissues and the
waiver of patient consent in this study
were approved by the Clinical Research
Ethics Board of the University of British
Columbia and were done in accor-
dance with the Declaration of Helsinki
guidelines.
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TO THE EDITOR
Nevus spilus, also known as speckled
lentiginous nevus, is a congenital hyper-
pigmented patch, which progressively
evolves, developing dark macules and
papules during childhood and adoles-
cence (Vidaurri-de la Cruz and Happle,
2006) (Figure 1a, b). Over time, nevus
spilus has been reported to give rise to
common lentigines, melanocytic nevi,
Spitz nevi, and melanoma (Bolognia,
1991; Aloi et al., 1995; Betti et al.,
1997; Vente et al., 2004). These conge-
nital lesions are postulated to result
from a postzygotic genetic alteration
of the melanocytic lineage, which gives
rise to a clone of melanocytes predis-
posed to developing neoplasms (Happle,
1993).
Using exome sequencing, we recently
identified an activating HRAS point
mutation (c.37G-4C, p.Gly13Arg) in a
nevus spilus giving rise to agminated
Spitz nevi that was absent from adjacent
normal skin (Sarin et al., 2013).
However, it remained unclear whether
this mutation is unique to this atypical
case or represented a common mutation
in nevi spili. In this report, we identify
the presence of the HRAS point muta-
tion (c.37G-4C, p.Gly13Arg) in eight
additional sporadic nevi spili, thus
implicating the HRAS mutation (c.37G-
4C, p.Gly13Arg) as the predominant
causative mutation for nevi spili.
Genomic DNA was isolated from
paraffin tissue biopsies of eight samples
that were clinically diagnosed as nevi
spili by board-certified dermatologists
and confirmed as being consistent with
nevi spili by board-certified dermato-
pathologists. These tissue biopsies were
obtained from the lentiginous areas
as well as the nevi within the lesion.
Phenotypic and histopathologic data on
each nevus spilus sample are detailed in
Supplementary Table S1 online. Initial
attempts at Sanger sequencing of whole
paraffin sections for the presence of
the HRAS point mutation (c.37G-4C,
p.Gly13Arg) were negative. We hypo-
thesized that the causative mutation
may be undetectable by traditional
Sanger sequencing as nevi spili melano-
cytes comprise a minute fraction of the
total cells in the section. One method
for enrichment of this small population
is through laser capture microdissection.
However, this technique is time and
labor intensive and thus not easily
adaptable into a screening assay. To
enrich for a potential HRAS mutation,
we used a rapid screening assay exploit-
ing the fact that the HRAS point mutation
(c.37G-4C, p.Gly13Arg) obliterates an
Aci1 enzymatic digestion site (Supple-
mentary Figures S1, S2 and Supple-
mentary Methods online). Briefly, DNA
isolated from whole paraffin sections
of nevi spili was amplified with HRAS
primers 50-CCTATCCTGGCTGTGTCCT
G-30 and 50-CAGGAGACCCTGTAGGAG
GA-30 spanning exon 2. The HRAS
exon 2 amplicon was then subjected to
digestion for 16hours at 37 degrees with
Aci1, which preferentially digests wild-
type HRAS sequences in the sample,
thereby enriching for DNA sequences
containing the HRAS mutation (c.37G-
4C, p.Gly13Arg). Following digestion,
the DNA was subjected to a second
round of amplification with nested HRAS
primers 50-CTCACCTCTATAGTGGGGT
CGT-30 and 50-TGAGGAGCGATGACG
GAATA-30 spanning the digestion site.
Sanger sequencing using the internal
primers in both directions now detected
this point mutation in all eight samples
but not in normal control skin (Figure 2a
and b). The mutation was also confirmed
using an independent set of HRAS
primers 50-ATGACGGAATATAAGCTG-30
and 50-CTCTATAGTGGGGTCGTA-30
for the second round amplification and
Sanger sequencing. Although the diges-
tion using Aci1 was incomplete as
evidenced by the persistent detection
of the wild-type allele, it was sufficient
to enrich the proportion of DNA con-
taining the HRAS mutation to detectable
levels.
Recently, activating HRAS mutations
were identified in the keratinocytes andAccepted article preview online 3 January 2014; published online 30 January 2014
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